Literature DB >> 23666852

IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.

Sensen Zhang1, Jiaren Xu, Shuang Wu, Rong Wang, Xiaoyan Qu, Wenjun Yu, Jiangyong Li, Lijuan Chen.   

Abstract

Interferon regulatory factor 4 (IRF4) is a member of the interferon regulatory family, which plays an important role in many lymphoid and myeloid malignancies. In the current study, using immunohistochemical staining, we found that IRF4 only expressed in plasma cells in bone marrow biopsy samples of multiple myeloma. IRF4-positive patients displayed increased disease stage (Durie-Salmon stage, p = 0.026; and International Staging System, p = 0.005). Silencing IRF4 in myeloma cell lines could inhibit myeloma cells proliferation and induce myeloma cell apoptosis, partly by JNK/Jun pathway. These results demonstrate that IRF4 plays important roles in myelomagenesis and disease progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23666852     DOI: 10.1007/s12032-013-0594-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

Review 1.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

2.  Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma.

Authors:  S Iida; P H Rao; M Butler; P Corradini; M Boccadoro; B Klein; R S Chaganti; R Dalla-Favera
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

Review 3.  The microenvironment and molecular biology of the multiple myeloma tumor.

Authors:  Miguel Lemaire; Sarah Deleu; Elke De Bruyne; Els Van Valckenborgh; Eline Menu; Karin Vanderkerken
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

Review 4.  Targeting IRF4 in autoimmune diseases.

Authors:  Wang-Dong Xu; Hai-Feng Pan; Dong-Qing Ye; Yuekang Xu
Journal:  Autoimmun Rev       Date:  2012-08-21       Impact factor: 9.754

5.  Fluorescent in situ hybridization studies in multiple myeloma.

Authors:  Ozge Ozalp Yuregir; Feride Iffet Sahin; Zerrin Yilmaz; Ebru Kizilkilic; Sema Karakus; Hakan Ozdogu
Journal:  Hematology       Date:  2009-04       Impact factor: 2.269

6.  A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes.

Authors:  Elke Glasmacher; Smita Agrawal; Abraham B Chang; Theresa L Murphy; Wenwen Zeng; Bryan Vander Lugt; Aly A Khan; Maria Ciofani; Chauncey J Spooner; Sascha Rutz; Jason Hackney; Roza Nurieva; Carlos R Escalante; Wenjun Ouyang; Dan R Littman; Kenneth M Murphy; Harinder Singh
Journal:  Science       Date:  2012-09-13       Impact factor: 47.728

7.  Cancer and the microenvironment: myeloma-osteoclast interactions as a model.

Authors:  Shmuel Yaccoby; Michele J Wezeman; Aminah Henderson; Michele Cottler-Fox; Qing Yi; Bart Barlogie; Joshua Epstein
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

8.  Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.

Authors:  Klaus Podar; Marc S Raab; Giovanni Tonon; Martin Sattler; Daniela Barilà; Jing Zhang; Yu-Tzu Tai; Hiroshi Yasui; Noopur Raje; Ronald A DePinho; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

9.  Shared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development.

Authors:  Michio Yamamoto; Takayuki Kato; Chie Hotta; Akira Nishiyama; Daisuke Kurotaki; Masahiro Yoshinari; Masamichi Takami; Motohide Ichino; Masatoshi Nakazawa; Toshifumi Matsuyama; Ryutaro Kamijo; Seiichi Kitagawa; Keiko Ozato; Tomohiko Tamura
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

10.  IRF4 is a suppressor of c-Myc induced B cell leukemia.

Authors:  Simanta Pathak; Shibin Ma; Long Trinh; James Eudy; Kay-Uwe Wagner; Shantaram S Joshi; Runqing Lu
Journal:  PLoS One       Date:  2011-07-27       Impact factor: 3.240

View more
  5 in total

1.  Screening and identification of key candidate genes and pathways in myelodysplastic syndrome by bioinformatic analysis.

Authors:  Ying Le
Journal:  PeerJ       Date:  2019-11-29       Impact factor: 2.984

Review 2.  Novel Methylation Biomarkers for Colorectal Cancer Prognosis.

Authors:  Alvaro Gutierrez; Hannah Demond; Priscilla Brebi; Carmen Gloria Ili
Journal:  Biomolecules       Date:  2021-11-19

3.  Deletion of Myeloid Interferon Regulatory Factor 4 (Irf4) in Mouse Model Protects against Kidney Fibrosis after Ischemic Injury by Decreased Macrophage Recruitment and Activation.

Authors:  Kensuke Sasaki; Andrew S Terker; Yu Pan; Zhilian Li; Shirong Cao; Yinqiu Wang; Aolei Niu; Suwan Wang; Xiaofeng Fan; Ming-Zhi Zhang; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2021-02-22       Impact factor: 14.978

4.  Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.

Authors:  Daeun Ryu; Hee Jin Kim; Je-Gun Joung; Hae-Ock Lee; Joon Seol Bae; Seok Jin Kim; Haesu Kim; Woong-Yang Park; Kihyun Kim
Journal:  Oncotarget       Date:  2016-07-26

5.  Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Authors:  Molly Went; Amit Sud; Helen Speedy; Nicola J Sunter; Asta Försti; Philip J Law; David C Johnson; Fabio Mirabella; Amy Holroyd; Ni Li; Giulia Orlando; Niels Weinhold; Mark van Duin; Bowang Chen; Jonathan S Mitchell; Larry Mansouri; Gunnar Juliusson; Karin E Smedby; Sandrine Jayne; Aneela Majid; Claire Dearden; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; Richard Rosenquist; Rowan Kuiper; Owen W Stephens; Uta Bertsch; Peter Broderick; Hermann Einsele; Walter M Gregory; Jens Hillengass; Per Hoffmann; Graham H Jackson; Karl-Heinz Jöckel; Jolanta Nickel; Markus M Nöthen; Miguel Inacio da Silva Filho; Hauke Thomsen; Brian A Walker; Annemiek Broyl; Faith E Davies; Markus Hansson; Hartmut Goldschmidt; Martin J S Dyer; Martin Kaiser; Pieter Sonneveld; Gareth J Morgan; Kari Hemminki; Björn Nilsson; Daniel Catovsky; James M Allan; Richard S Houlston
Journal:  Blood Cancer J       Date:  2018-12-21       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.